Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Neuroscience PhD Program, Mayo Graduate School of Biomedical Sciences, Mayo Clinic, Jacksonville, FL, USA.
Autophagy. 2023 Jun;19(6):1711-1732. doi: 10.1080/15548627.2022.2151294. Epub 2022 Dec 5.
The ubiquitin (Ub) kinase-ligase pair PINK1-PRKN mediates the degradation of damaged mitochondria by macroautophagy/autophagy (mitophagy). PINK1 surveils mitochondria and upon stress accumulates on the mitochondrial surface where it phosphorylates serine 65 of Ub to activate PRKN and to drive mitochondrial turnover. While loss of either PINK1 or PRKN is genetically linked to Parkinson disease (PD) and activating the pathway seems to have great therapeutic potential, there is no formal proof that stimulation of mitophagy is always beneficial. Here we used biochemical and cell biological methods to study single nucleotide variants in the activation loop of PINK1 to modulate the enzymatic function of this kinase. Structural modeling and kinase assays were used to investigate the molecular mechanism of the PINK1 variants. In contrast to the PD-linked PINK1 mutation that diminishes Ub kinase activity, we found that the PINK1 variant significantly boosted Ub phosphorylation beyond levels of PINK1 wild type. This resulted in augmented PRKN activation, mitophagy rates and increased viability after mitochondrial stress in midbrain-derived, gene-edited neurons. Mechanistically, the G411A variant stabilizes the kinase fold of PINK1 and transforms Ub to adopt the preferred, C-terminally retracted conformation for improved substrate turnover. In summary, we identify a critical role of residue 411 for substrate receptivity that may now be exploited for drug discovery to increase the enzymatic function of PINK1. The genetic substitution of Gly411 to Ala increases mitophagy and may be useful to confirm neuroprotection and might serve as a critical positive control during therapeutic development.: ATP: adenosine triphosphate; CCCP: carbonyl cyanide m-chlorophenyl hydrazone; Ub-CR: ubiquitin with C-terminally retracted tail; CTD: C-terminal domain (of PINK1); ELISA: enzyme-linked immunosorbent assay; HCI: high-content imaging; IB: immunoblot; IF: immunofluorescence; NPC: neuronal precursor cells; MDS: molecular dynamics simulation; PD: Parkinson disease; p-S65-Ub: ubiquitin phosphorylated at Ser65; RMSF: root mean scare fluctuation; TOMM: translocase of outer mitochondrial membrane; TVLN: ubiquitin with T66V and L67N mutation, mimics Ub-CR; Ub: ubiquitin; WT: wild-type.
泛素(Ub)激酶-连接酶对 PINK1-PRKN 通过巨自噬/自噬(mitophagy)介导受损线粒体的降解。PINK1 监测线粒体,在应激下积累在线粒体表面,在那里它磷酸化 Ub 的丝氨酸 65 以激活 PRKN 并驱动线粒体周转。虽然 PINK1 或 PRKN 的缺失都与帕金森病(PD)有关,并且激活该途径似乎具有巨大的治疗潜力,但没有正式的证据表明刺激线粒体自噬总是有益的。在这里,我们使用生化和细胞生物学方法研究了 PINK1 激活环中的单核苷酸变异,以调节这种激酶的酶促功能。结构建模和激酶测定用于研究 PINK1 变体的分子机制。与降低 Ub 激酶活性的 PD 相关的 PINK1 突变相反,我们发现 PINK1 变体显著提高了 Ub 磷酸化水平,超过了 PINK1 野生型的水平。这导致 PRKN 激活、线粒体自噬率增加,并在中脑衍生的、基因编辑的神经元中线粒体应激后提高了存活率。从机制上讲,G411A 变体稳定了 PINK1 的激酶折叠,并将 Ub 转化为采用首选的、C 端回缩构象,以提高底物周转率。总之,我们确定了残基 411 对底物接受性的关键作用,这可能现在可用于药物发现,以提高 PINK1 的酶促功能。甘氨酸 411 突变为丙氨酸的遗传替代增加了线粒体自噬,可能有助于确认神经保护作用,并可能作为治疗开发过程中的关键阳性对照。